Methodology: 4/5
Usefulness: 4.5/5

Polack FP, et al. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

Editorial: SARS-CoV-2 Vaccination – An Ounce (Actually, Much Less) of Prevention.

Question/methods: Multinational, placebo-controlled, observer-blinded, pivotal efficacy trial comparing the safety and efficacy of two doses of BNT162b2, given 3 weeks apart, to placebo.
Findings: A two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. 
Limitations: conducted and funded by Pfizer, long-term effects unknown, duration of immune response unknown, few severe cases of COVID-19. 

Interpretation: The Pfizer Covid-19 vaccine is effective at preventing COVID-19 infection and has a similar safety profile to other vaccines.  

By: Dr. Simon Wells

 

Hans Rosenberg
Dr. Rosenberg is an emergency physician at the Ottawa Hospital, assistant professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.